News/ News/ R&D Sanofi pauses enrolment in ex-US tolebrutinib trials Phil Taylor BTK inhibitor, evobrutinib, Merck KGaA, multiple sclerosis, safety, Sanofi 0 Comment Sanofi has paused recruitment in its international phase 3 trials of BTK inhibitor tolebrutinib for multiple sclerosis, although Share X Sanofi pauses enrolment in ex-US tolebrutinib trials https://pharmaphorum.com/news/sanofi-pauses-enrolment-in-ex-us-tolebrutinib-trials/
R&D/ Views & Analysis/ Views and analysis Tackling the remaining challenges of multiple sclerosis George Underwood evobrutinib, Merck KGaA, multiple sclerosis 0 Comment With Merck KGaA’s multiple sclerosis drug evobrutinib entering phase 3 trials, we spoke to the company’s Fernando Dangond Share X Tackling the remaining challenges of multiple sclerosis https://pharmaphorum.com/r-d/views-analysis-r-d/tackling-the-remaining-challenges-of-multiple-sclerosis/
BTK inhibitor, evobrutinib, Merck KGaA, multiple sclerosis, safety, Sanofi
0 Comment
